PTCT | tickerfilter.com

Fundamental analysis

17%

Profitability 0%

Dept financing 19%

Liquidity 75%

Performance 20%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.42%

1 Month

-2.35%

3 Months

10.04%

6 Months

17.08%

1 Year

54.82%

2 Year

-9.81%

Key data

Stock price

$49.76

P/E Ratio

0.00

DAY RANGE

$49.11 - $50.40

EPS

-$5.95

52 WEEK RANGE

$28.72 - $58.38

52 WEEK CHANGE

$54.77

MARKET CAP

3.481 B

YIELD

N/A

SHARES OUTSTANDING

76.924 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-06-2025

BETA

2.12

PUBLIC FLOAT

AVERAGE 10 VOLUME

$841,616

AVERAGE 30 VOLUME

$1,244,686

Company detail

CEO: Stuart W. Peltz
Region: US
Website: ptcbio.com
Employees: 1,410
IPO year: 2013

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

PTC Therapeutics focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; Tegsedi and Waylivra for the. treatment of rare diseases in Latin America and the Caribbean. PTC518 is being developed for Huntington's disease.

PTCT - PTC THERAPEUTICS, INC.